Synendos Therapeutics won Venture Kick Stage II and was awarded with CHF 40’000. This funding will help Synendos to build solid foundation for successful execution of the venture.
May 2019 // Funding
Updated: Nov 6, 2020
top of page
FOUNDING TEAM
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
FOUNDING TEAM
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
FOUNDING TEAM
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
FOUNDING TEAM
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque leo mauris, pretium et ipsum quis, convallis ullamcorper sem. Maecenas elementum nibh nisi, eu auctor nunc pulvinar vitae. Donec ut interdum leo. Nam ac felis semper, facilisis nulla venenatis, molestie nibh.
PD Dr. Andrea Chicca
Project leader/senior scientist at UniBern.
2 years in pharma industry.
8 years of research activity on the ECS
Prof. Dr. Jürg Gertsch
Full Professor at UniBern.
Collaboration with pharma industry.
10+ years of research activity on the ECS.
Recent Posts
See AllSynendos Secures Innosuisse Funding to Advance Clinical Development of SYT-510 Synendos AG is excited to announce that it has been...
Synendos Series A Extension Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of...
Synendos Therapeutics Raises CHF 20 Million in Series A Financing.
bottom of page
Comments